Dec. 19 at 5:02 AM
$FLHLF Research interest in the potential of psychedelic drugs to treat mental health conditions including depression, anxiety, existential distress in serious medical illnesses, post-traumatic stress disorder, and addiction has been growing. The U.S. Food and Drug Administration (FDA) granted “breakthrough therapy” designation to psilocybin-assisted psychotherapy for both major depressive disorder in 2019 and treatment-resistant depression in 2018. The FDA may also grant this designation for treatments for serious or life-threatening conditions where preliminary evidence suggests the treatment may improve the conditions substantially more than other available options.
